v3.26.3
GENERAL (Narrative) (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 4 Months Ended 6 Months Ended
Jun. 11, 2026
USD ($)
Feb. 10, 2026
$ / shares
shares
Feb. 10, 2026
USD ($)
$ / shares
shares
Jul. 17, 2026
USD ($)
Apr. 17, 2025
USD ($)
Jun. 30, 2026
USD ($)
Apr. 21, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
 [1]
Jun. 30, 2026
₪ / shares
Jun. 30, 2026
USD ($)
$ / shares
shares
Dec. 31, 2025
₪ / shares
Dec. 31, 2025
USD ($)
shares
Disclosure of detailed information about business combination [line items]                          
Operating loss               $ 5,387 $ 4,853        
Loss from discontinued operations               (492) (3,579)        
Proceeds from issuance of ordinary shares in warrant inducement transaction, net of issuance expenses               3,206 0        
Net operating cash outflows               (4,928) (7,483)        
Accumulated deficit                     $ (290,194)   $ (282,556)
Ordinary shares issued | shares                     13,535,843   8,718,193
Ordinary shares per share | ₪ / shares                   ₪ 0.2   ₪ 0.2  
Gross proceeds from ordinary shares               805 4,283        
Finance costs               4,045 1,011        
Finance income               2,304 $ 1,839        
Amount from redeem SAFE         $ 10,000                
Warrants [member]                          
Disclosure of detailed information about business combination [line items]                          
Finance costs               3,811          
Finance income               2,108          
Inducement Letter Agreement [Member] | Warrants [member]                          
Disclosure of detailed information about business combination [line items]                          
Number of underlying ordinary shares purchased | shares   3,384,616 3,384,616                    
Reduced exercise price | $ / shares   $ 1 $ 1                    
Exercise price per warrant | $ / shares   $ 1.25                      
Inducement Letter Agreement [Member] | New Warrants [Member]                          
Disclosure of detailed information about business combination [line items]                          
New ordinary share purchase warrants | shares   5,076,924 5,076,924                    
Proceeds from issuance of ordinary shares in warrant inducement transaction, net of issuance expenses     $ 3,385                    
Biomica Ltd [Member]                          
Disclosure of detailed information about business combination [line items]                          
Dividend distributed to shareholders           $ 2,700              
Dividends paid to non-controlling interests           1,350              
ATM offering [Member]                          
Disclosure of detailed information about business combination [line items]                          
Ordinary shares issued | shares                     1,431,386    
Sell price per share | $ / shares                     $ 0.582    
Gross proceeds from ordinary shares               $ 833          
Aggregate offering price $ 2,927     $ 3,288                  
Lavie Bio Ltd [Member]                          
Disclosure of detailed information about business combination [line items]                          
Dividend distributed to shareholders           4,250              
Dividends paid to non-controlling interests           $ 1,322              
Lavie Bio Ltd [Member] | ICL Group [Member]                          
Disclosure of detailed information about business combination [line items]                          
Consideration received for sale of project             $ 15,250            
Evogene’s Microboost Ai Tech-engine [Member] | ICL Group [Member]                          
Disclosure of detailed information about business combination [line items]                          
Consideration received for sale of project             $ 3,464            
[1] Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.